top of page
  • Writer's pictureNammi Therapeutics

Nammi Therapeutics Awarded Grant by California Institute for Regenerative Medicine (CIRM)

Updated: Feb 9, 2023

The governing Board of the California Institute for Regenerative Medicine (CIRM) funded a Phase 3 clinical trial to support the development of a safer, more tolerable alternative.

The CIRM Board awarded $3,999,113 to Dr. David Stover and Nammi Therapeutics to complete the manufacture and testing needed to gain FDA permission for a clinical trial for multiple myeloma and advanced solid tumors. The therapy QXL 138AM, a “masked immunocytokine,” binds to and kills the tumor by activating the immune system.

December 15 ICOC News Release for Posting -
Download PDF • 105KB

177 views0 comments

Recent Posts

See All


bottom of page